← Leaderboards
Syreeta L Tilghman
Xavier University Of Louisiana
$2,263,079
Attributed
$2,263,079
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $368.9K · FY2013–25$500K$375K$250K$125K$0
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$2,263,079 · 3
By mechanism
SC1$1,472,370 · 1
U54$416,278 · 1
SC2$374,431 · 1
Top collaborators
No co-investigators on record.
Most similar at Xavier University Of Louisiana
Same institution · by research overlap
- Florastina L Payton-Stewart$750,000
- Kathleen M Morgan$743,310
Others in their field
Top investigators on “Research Personnel”
- David Heimbrook · Leidos Biomedical Research, Inc.$701,463,488
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Leonard Freedman · Leidos Biomedical Research, Inc.$557,978,666
- Tracy L Nolen · Research Triangle Institute$474,487,152
- David R. Weir · University Of Michigan At Ann Arbor$364,053,504
- Judith S. Currier · University Of California Los Angeles$284,675,012
Research focus
Research PersonnelTumorLetrozoleRefractorySeriesTreatment StrategyHormone TherapyIn VivoModalityPathway InteractionsResistanceResistance DevelopmentAromatase InhibitorsBreast Cancer CellCell ProliferationGrowthInnovationIn VitroCellsMalignant Breast NeoplasmNeoplasm MetastasisNovel StrategiesEstrogensWoman
Grant awards (9)
Research Project-1: Midasin, A Novel Biomarker for Endocrine Resistant Breast Cancer$205,753
U54 · FY2025 · MD · contact PI
Research Project-1: Midasin, A Novel Biomarker for Endocrine Resistant Breast Cancer$210,525
U54 · FY2024 · MD · contact PI
Second line breast cancer therapy alters aromatase inhibitor resistant metastasis$368,872
SC1 · FY2021 · GM · contact PI
Second line breast cancer therapy alters aromatase inhibitor resistant metastasis$368,872
SC1 · FY2020 · GM · contact PI
Second line breast cancer therapy alters aromatase inhibitor resistant metastasis$368,872
SC1 · FY2019 · GM · contact PI
Second line breast cancer therapy alters aromatase inhibitor resistant metastasis$365,754
SC1 · FY2018 · GM · contact PI
Second line breast cancer therapy through a novel Phytoantiestrogen$126,071
SC2 · FY2015 · CA · contact PI
Second line breast cancer therapy through a novel Phytoantiestrogen$122,289
SC2 · FY2014 · CA · contact PI
Second line breast cancer therapy through a novel Phytoantiestrogen$126,071
SC2 · FY2013 · CA · contact PI